Bone marrow transplantation for chronic myelogenous leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential cure for chronic myelogenous leukemia (CML).
• HLA-matched sibling transplants in the chronic phase of CML yield disease-free survival rates of 49-69%.
• Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity post-HSCT.

Purpose of the Study:

• To review strategies for improving HSCT outcomes in CML.
• To evaluate methods aimed at reducing GVHD and its impact on survival.
• To assess transplant outcomes in advanced phases of CML.

Main Methods:

• Analysis of existing literature on HSCT protocols for CML.
• Investigation of T-cell depletion techniques to mitigate GVHD.
• Review of conditioning regimens, including busulfan and cyclophosphamide, for advanced CML.

Main Results:

• T-cell depletion has shown improved survival in older patients but with variable effects on GVHD, graft failure, and relapse.
• Transplantation in advanced CML phases results in lower survival due to disease resistance.
• Busulfan and cyclophosphamide conditioning demonstrate improved survival in advanced CML.

Conclusions:

• HSCT remains a curative option for CML, particularly in the chronic phase with HLA-matched donors.
• GVHD remains a significant barrier to HSCT success, necessitating strategies for its reduction.
• Conditioning regimens like busulfan and cyclophosphamide show promise for improving outcomes in advanced CML.